| Identification | Back Directory | [Name]
Nodakenin | [CAS]
495-31-8 | [Synonyms]
NODAKENIN
AliNodakenin
Nodakenin USP/EP/BP
Nodakenin, 98%, from Angelica decursiva (Miq.) Franch. & Sav.
2-(7-Oxo-2,3-dihydro-7H-furo[3,2-g]chromen-3-yl)-2-propanyl β-D-glucopyranoside
(R)-2-[1-(β-D-Glucopyranosyloxy)-1-methylethyl]-2,3-dihydro-7H-furo[3,2-g][1]benzopyran-7-one
7H-Furo[3,2-g][1]benzopyran-7-one, 2-[1-(β-D-glucopyranosyloxy)-1-methylethyl]-2,3-dihydro-, (2R)-
(2R)-2-[2-[(2S,3R,4S,5S,6R)-3,4,5-Trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypropan-2-yl]-2,3-dihydrofuro[3,2-g]chromen-7-one | [Molecular Formula]
C20H24O9 | [MDL Number]
MFCD09953919 | [MOL File]
495-31-8.mol | [Molecular Weight]
408.4 |
| Chemical Properties | Back Directory | [Melting point ]
melting at 216° | [alpha ]
D30 +56.6° | [Boiling point ]
657.1±55.0 °C(Predicted) | [density ]
1.51±0.1 g/cm3(Predicted) | [storage temp. ]
Keep in dark place,Sealed in dry,2-8°C | [solubility ]
Chloroform (Slightly, Sonicated), DMSO (Slightly) | [form ]
Solid | [pka]
12.90±0.70(Predicted) | [color ]
Off-White to Pale Beige | [InChIKey]
HXCGUCZXPFBNRD-VPVUCYOBNA-N | [SMILES]
C([C@@H]1OC2=CC3OC(=O)C=CC=3C=C2C1)(C)(C)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O |&1:1,18,19,20,22,24,r| |
| Hazard Information | Back Directory | [Chemical Properties]
White crystalline powder, soluble in methanol, derived from the plant Peucedanum purpurogenum and Angelica radix. | [Uses]
Nodakenin is a compound used for inhibiting influenza virus including Nodakenin and/or Nodakenetin. | [Definition]
ChEBI:Nodakenin is a furanocoumarin. | [Synthesis]
1. Rhizome of Qianghuo is extracted with ethanol, concentrated, and acid-hydrolyzed. The hydrolysate is passed through macroporous resin. Elution with ethanol of varying concentrations yields an extract rich in the target.
2. The extract is mixed with | [in vivo]
Nodakenin (10 mg/kg, p.o.) reverses scopolamine-induced cognitive impairments in the passive avoidance test and the Y-maze test[1].
Nodakenin (10 mg/kg, p.o.) reduces escape latency during training in the Morris water maze test[1].
| Animal Model: | Male ICR mice
| | Dosage: | 2.5, 5, 10 and 20 mg/kg
| | Administration: | p.o, single dose
| | Result: | Reversed in step-through latency induced by scopolamine. |
| [IC 50]
AChE |
|
|